share_log

華領醫藥-B：有關委任執行董事的補充公告

HUA MEDICINE-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO APPOINTMENT OF EXECUTIVE DIRECTOR

香港交易所 ·  Mar 15 04:47
Summary by Moomoo AI
華領醫藥-B（股份代號：2552）於2024年3月15日發布補充公告，詳述張怡博士自2024年1月1日起被委任為執行董事的相關資訊。公告補充提供張博士持有本公司約1.10%的股份，包括直接持有的股份及根據公司股份激勵計劃授予的購股權。張博士確認，除已披露資訊外，無需根據上市規則披露的其他資料，且無其他事宜需提請股東注意。該公告中的其他資料維持不變。
華領醫藥-B（股份代號：2552）於2024年3月15日發布補充公告，詳述張怡博士自2024年1月1日起被委任為執行董事的相關資訊。公告補充提供張博士持有本公司約1.10%的股份，包括直接持有的股份及根據公司股份激勵計劃授予的購股權。張博士確認，除已披露資訊外，無需根據上市規則披露的其他資料，且無其他事宜需提請股東注意。該公告中的其他資料維持不變。
HUA LEIN PHARMACEUTICAL-B (STOCK CODE: 2552) ISSUED A SUPPLEMENTAL NOTICE ON 15 MARCH 2024 DETAILING THE INFORMATION REGARDING THE APPOINTMENT OF DR. CHEUNG YI AS EXECUTIVE DIRECTOR FROM 1 JANUARY 2024. The announcement is supplemented by the provision of approximately 1.10% of Dr. Zhang's shares in the Company, including shares directly held and share purchase rights granted under the Company's Share Incentive Program. Dr. Zhang confirms that no other information is required to be disclosed in accordance with the Listing Rules and that no other matters should be brought to the attention of shareholders other than the disclosed information. Other information in this announcement remains unchanged.
HUA LEIN PHARMACEUTICAL-B (STOCK CODE: 2552) ISSUED A SUPPLEMENTAL NOTICE ON 15 MARCH 2024 DETAILING THE INFORMATION REGARDING THE APPOINTMENT OF DR. CHEUNG YI AS EXECUTIVE DIRECTOR FROM 1 JANUARY 2024. The announcement is supplemented by the provision of approximately 1.10% of Dr. Zhang's shares in the Company, including shares directly held and share purchase rights granted under the Company's Share Incentive Program. Dr. Zhang confirms that no other information is required to be disclosed in accordance with the Listing Rules and that no other matters should be brought to the attention of shareholders other than the disclosed information. Other information in this announcement remains unchanged.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more